UroGen Pharma Statistics
Total Valuation
UroGen Pharma has a market cap or net worth of $192.27 million. The enterprise value is $118.23 million.
Important Dates
The last earnings date was Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
UroGen Pharma has 46.11 million shares outstanding. The number of shares has increased by 40.86% in one year.
| Current Share Class | 46.11M |
| Shares Outstanding | 46.11M |
| Shares Change (YoY) | +40.86% |
| Shares Change (QoQ) | +0.83% |
| Owned by Insiders (%) | 5.09% |
| Owned by Institutions (%) | 73.61% |
| Float | 36.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.06 |
| Forward PS | 1.82 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.65
| Current Ratio | 5.65 |
| Quick Ratio | 5.13 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.56 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -29.80% |
| Return on Invested Capital (ROIC) | -96.25% |
| Return on Capital Employed (ROCE) | -51.97% |
| Revenue Per Employee | $390,940 |
| Profits Per Employee | -$589,068 |
| Employee Count | 235 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 1.28 |
Taxes
In the past 12 months, UroGen Pharma has paid $3.17 million in taxes.
| Income Tax | 3.17M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.70% in the last 52 weeks. The beta is 0.67, so UroGen Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | -67.70% |
| 50-Day Moving Average | 10.39 |
| 200-Day Moving Average | 11.62 |
| Relative Strength Index (RSI) | 24.48 |
| Average Volume (20 Days) | 1,922,215 |
Short Selling Information
The latest short interest is 5.02 million, so 10.88% of the outstanding shares have been sold short.
| Short Interest | 5.02M |
| Short Previous Month | 5.06M |
| Short % of Shares Out | 10.88% |
| Short % of Float | 13.66% |
| Short Ratio (days to cover) | 7.74 |
Income Statement
In the last 12 months, UroGen Pharma had revenue of $91.87 million and -$138.43 million in losses. Loss per share was -$3.04.
| Revenue | 91.87M |
| Gross Profit | 82.39M |
| Operating Income | -106.86M |
| Pretax Income | -100.36M |
| Net Income | -138.43M |
| EBITDA | -106.58M |
| EBIT | -106.86M |
| Loss Per Share | -$3.04 |
Full Income StatementBalance Sheet
The company has $195.89 million in cash and $126.36 million in debt, giving a net cash position of $74.04 million or $1.61 per share.
| Cash & Cash Equivalents | 195.89M |
| Total Debt | 126.36M |
| Net Cash | 74.04M |
| Net Cash Per Share | $1.61 |
| Equity (Book Value) | -46.46M |
| Book Value Per Share | -1.01 |
| Working Capital | 195.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$107.06 million and capital expenditures -$339,000, giving a free cash flow of -$107.39 million.
| Operating Cash Flow | -107.06M |
| Capital Expenditures | -339,000 |
| Free Cash Flow | -107.39M |
| FCF Per Share | -$2.33 |
Full Cash Flow StatementMargins
Gross margin is 89.68%, with operating and profit margins of -116.31% and -150.68%.
| Gross Margin | 89.68% |
| Operating Margin | -116.31% |
| Pretax Margin | -147.23% |
| Profit Margin | -150.68% |
| EBITDA Margin | -116.01% |
| EBIT Margin | -116.31% |
| FCF Margin | n/a |
Dividends & Yields
UroGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -40.86% |
| Shareholder Yield | -40.86% |
| Earnings Yield | -72.00% |
| FCF Yield | -55.86% |
Analyst Forecast
The average price target for UroGen Pharma is $36.75, which is 781.30% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $36.75 |
| Price Target Difference | 781.30% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 57.42% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
UroGen Pharma has an Altman Z-Score of -3.85 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.85 |
| Piotroski F-Score | 2 |